Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Avidity Biosciences Inc (RNA)

Avidity Biosciences Inc (RNA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 902,573
  • Shares Outstanding, K 37,670
  • Annual Sales, $ 6,790 K
  • Annual Income, $ -44,360 K
  • 60-Month Beta 1.53
  • Price/Sales 126.71
  • Price/Cash Flow N/A
  • Price/Book 2.74
Trade RNA with:

Options Overview

Details
  • Implied Volatility 85.86%
  • Historical Volatility 113.03%
  • IV Percentile 28%
  • IV Rank 53.00%
  • IV High 120.61% on 07/19/21
  • IV Low 46.69% on 07/22/21
  • Put/Call Vol Ratio 0.15
  • Today's Volume 23
  • Volume Avg (30-Day) 39
  • Put/Call OI Ratio 0.24
  • Today's Open Interest 68
  • Open Int (30-Day) 63

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.75
  • Number of Estimates 2
  • High Estimate -0.60
  • Low Estimate -0.89
  • Prior Year -0.31
  • Growth Rate Est. (year over year) -141.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.10 +32.38%
on 09/01/21
24.69 -2.96%
on 09/17/21
+5.23 (+27.92%)
since 08/17/21
3-Month
17.58 +36.29%
on 08/03/21
29.59 -19.03%
on 06/28/21
-2.84 (-10.60%)
since 06/17/21
52-Week
17.58 +36.29%
on 08/03/21
36.04 -33.52%
on 09/22/20
-9.41 (-28.20%)
since 09/17/20

Most Recent Stories

More News
Avidity Biosciences to Participate in Upcoming Investor Conferences

/PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced...

RNA : 23.96 (+4.95%)
Avidity Biosciences Announces Changes to its Board of Directors

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA) a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the...

RNA : 23.96 (+4.95%)
European Medicines Agency (EMA) Grants Orphan Designation for AOC 1001

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced...

RNA : 23.96 (+4.95%)
Avidity Biosciences Enters Into Collaboration with FSHD Clinical Trial Network to Support Development of Biomarkers for Future Clinical Trial Use

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today...

RNA : 23.96 (+4.95%)
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 9.09% and 73.80%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

RNA : 23.96 (+4.95%)
Avidity Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today...

RNA : 23.96 (+4.95%)
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock

Aug. 3, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™),...

RNA : 23.96 (+4.95%)
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today...

RNA : 23.96 (+4.95%)
Will Avidity Biosciences, Inc. (RNA) Report Negative Q2 Earnings? What You Should Know

Avidity Biosciences, Inc. (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RNA : 23.96 (+4.95%)
Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)

/PRNewswire/ -- Avidity Biosciences, Inc. (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs), today announced...

RNA : 23.96 (+4.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the...

See More

Key Turning Points

3rd Resistance Point 26.76
2nd Resistance Point 25.72
1st Resistance Point 24.84
Last Price 23.96
1st Support Level 22.93
2nd Support Level 21.89
3rd Support Level 21.01

See More

52-Week High 36.04
Fibonacci 61.8% 28.99
Fibonacci 50% 26.81
Fibonacci 38.2% 24.63
Last Price 23.96
52-Week Low 17.58

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar